Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
D&D Pharmatech
★
D&D Pharmatech Hosts NDR for Institutional Investors on Zabopegduptide MASH Phase 2 Biopsy Results
06/02/2026, 08:46 AM
EXCH
D&D Pharmatech
★★★★
D&D Pharmatech's DD01 Phase 2 MASH Trial Achieves Statistical Significance in All 48-Week Liver Biopsy Endpoints, Boosting Accelerated Approval Prospects
05/27/2026, 09:48 AM
OTHR
D&D Pharmatech
★
Outside Director Change Disclosure (No Change)
05/18/2026, 03:56 PM
OWNR
D&D Pharmatech
★
Submission of Report on Ownership of Specific Securities by Executives and Major Shareholders
05/15/2026, 04:30 PM
PERI
D&D Pharmatech
★
D&D Pharmatech Q1 2026: Operating loss widens, but DD01 Ph2 success and pipeline progress
05/15/2026, 02:48 PM
EXCH
D&D Pharmatech
★
Result of Issuance of 2nd Convertible Bonds (KRW 226.5 Billion)
05/03/2026, 07:00 AM